

Creating Global Solutions

AusBiotech2010
AUSTRALIA'S BIOTECHNOLOGY CONFERENCE

National Conference

19 to 22 October 2010

Melbourne Convention and Exhibition Centre

www.ausbiotech2010.com.au

Victoria
AUSTRALIA

BioNet™
Asia Pacific

AUSBIOTECH 2010 PROGRAM*

TUESDAY 19 OCTOBER

8:00am – 7:00pm	DELEGATE REGISTRATION DESK OPEN <i>Concourse, Melbourne Exhibition Centre (Clarendon St end)</i>
8:00am – 4:00pm	AUSBIOTECH AUSTRALASIAN LIFE SCIENCE INVESTMENT SUMMIT <i>By Invitation Only</i> <i>AusBiotech Australasian Life Sciences Summit - Hilton on the Park, East Melbourne</i> <i>Sponsored by Australian Securities Exchange, Australian Trade Commission, Blueprint Life Science Group, RBS Morgan, Buchan and State Government of Victoria</i>
9:00am – 5:00pm	SATELLITE EVENTS 9:00am – 4:30pm BioBasics in one day - industry knowledge for the non-scientist Meeting Room 3, Level 2, Melbourne Exhibition Centre, 2 Clarendon Street, Melbourne Separate registration required, further information at www.ausbiotech2010.com.au 9:00am – 4:30pm MBA in a Day – business basics for the bioscientist course Meeting Room 2, Level 2, Melbourne Exhibition Centre, 2 Clarendon Street, Melbourne Separate registration required, further information at www.ausbiotech2010.com.au 9:00am – 4:30pm Smart IP Management – Putting the IP Manual into Practice Meeting Room 1, Level 2, Melbourne Exhibition Centre, 2 Clarendon Street, Melbourne Separate registration required, further information at www.ausbiotech2010.com.au

2:00pm – 5:00pm	BIOINDUSTRY EXHIBITION HALL OPEN TO ALL DELEGATES
3:30pm – 4:00pm	Afternoon Tea - BioIndustry Exhibition Hall
5:00pm – 5:30pm	Coaches to Government House depart Melbourne Convention Centre, Porte Cochere Main Entrance, Convention Centre Place, opposite Hilton South Wharf Hotel Note: car parking is available on the grounds of Government House for registered delegates attending the Welcome Reception from 5:00pm
6:00pm – 7:30pm	AUSBIOTECH 2010 WELCOME RECEPTION For registered delegates only <i>Government House</i> Sponsored by State Government of Victoria
From 7:00pm	Coaches depart Government House to return delegates to the Melbourne Convention Centre

WEDNESDAY 20 OCTOBER

7:00am – 9:00am	SATELLITE EVENT Davies Collison Cave Breakfast Meeting Room 212, Melbourne Convention Centre Separate registration required, further information at www.ausbiotech2010.com.au
9:00am – 11:00am <i>Auditorium, Level 2, Melbourne Exhibition Centre</i>	OPENING OF AUSBIOTECH 2010 – <i>Auditorium, Level 2, Melbourne Exhibition Centre</i> AusBiotech 2010 to be officially opened by The Hon Gavin Jennings MLC, Minister for Innovation, State Government of Victoria & Dr Anna Lavelle, Chief Executive Officer, AusBiotech Ltd AWARD PRESENTATIONS AusBiotech 2010 Excellence Awards –presented by Dr Deborah Rathjen, Chair, AusBiotech Ltd & Dr Stella Xu, Executive Director, Roche Partnering Asia, Shanghai, China Sponsored by Roche AusBiotech–GSK Student Awards – presented by Dr Anna Lavelle, Chief Executive Officer, AusBiotech Ltd & Dr Ashley Bates, Head of R&D Alliances Australia & New Zealand, GlaxoSmithKline Sponsored by GlaxoSmithKline PLENARY 1 - Introduction: Dr Anna Lavelle, Chief Executive Officer, AusBiotech Ltd Speaker: Mr James C. Greenwood, President and CEO, Biotechnology Industry Organization, Washington D.C., United States <i>“Fulfilling the Promise”</i> Sponsored by State Government of Victoria PLENARY 2 - Introduction: Dr Daniel Pascheles, Vice-President, Head Global Competitive Intelligence, Merck & Co., Inc., New Jersey, United States Speaker: Dr David Nicholson, Senior Vice President, Worldwide Licensing and Knowledge Management, Merck Research Laboratories, New Jersey, United States <i>“Today’s Merck: Partnership Opportunities Continue to Grow”</i> Additional comments: Dr Bornadata Bain, Global Research and Analysis Director, Datamonitor Healthcare, United States <i>“Key Strategic Trends shaping the Pharmaceutical Industry to 2014”</i> Sponsored by Merck Sharp & Dohme

11:30am – 1:00pm

Concurrent Sessions:
*Melbourne Exhibition Centre***1.
MEDTECH
Meeting Room 1, Level 2****Cell therapy commercialisation: Look think and act from a different point of view**

To highlight the challenges being faced in the exciting and rapidly emerging Cell Therapy market, how companies around the world are addressing these issues and the vital role that Australian companies are currently playing.

Chair: Dr David Haylock, Research Scientist, Materials Science and Engineering, CSIRO

Speakers:
Associate Professor Geoff Symonds, Chief Scientific Officer, Calimmune Australia

Dr Kilian Kelly, Director Regulatory and Clinical, Mesoblast Limited

Dr Sunil Mehta, Director Technology Development, KBI Biopharma Inc., North Carolina, United States

Ian Fitzpatrick, Manager Manufacturing Innovation Group, Invetech Pty Ltd

**2.
HUMAN HEALTH
Meeting Room 3, Level 2****Regulation in Key Markets**

This session deals with regulatory aspects of developing biotechnology products intended for key global markets, with a principal focus on the US and European Union. Highly experienced speakers with many years of experience in direct interaction with Agencies in Europe and the US will discuss topical issues related to product development planning, clinical trial and pre-approval processes, as well as some practical tips and pitfalls in navigating the complex maze of regulatory processes in key markets.

Chair: Alek Safarian, Chief Executive Officer, Novotech

Speakers:
Michele Yelmene, Regulatory Affairs & Quality Assurance, Advisor to Industry, California, United States
"FDA 101 – A Roadmap for Getting Started"

Dr Chaline Brown, Senior Director Clinical Affairs, Ground Zero Pharmaceuticals Ltd, California, United States
"Dealing with the FDA – What's Hot?"

Dr Dianne Jackson-Matthews, Director, ERA Consulting (Australia) Pty Ltd
"Regulation of Biotech Products – Keeping Your Cool in the EU"

**3.
AG / INDUSTRIAL / FOOD
Meeting Room 2, Level 2****Biofuels - Algae as a Factory**

Chair: Dr Susan Pond AM, Professor, Dow Sustainability Program, US Studies Centre

Speakers:
Associate Professor Ben Hankamer, Director of the Solar Biofuels Consortium, Division of Chemistry and Structural Biology, The Institute for Molecular Bioscience

Professor Rocky De Nys, Head of Aquaculture, James Cook University

Dr Sasi Nayar, South Australian Research and Development Institute

**4.
INVESTMENT / BUSINESS
Suite 1, Level 5****International Financing – new options and opportunities**

This session will outline several new innovative finance options now available to Australian companies and introduce key international investors who have invested and are interested in investing in Australian life science companies

Chair: Jeremy Curnock – Cook, Managing Director, IB Fund Pty Ltd

Speakers:
Malcolm Thompson, La Jolla Cove Investors, United States

Todd C. Davis, Co-Founder and Managing Director, Cowen Healthcare Royalty Partners, United States

Doug Onsi, Managing Director, Healthcare Ventures, United States

Rudolf Gygax, Managing Partner, Nextech Venutres Ltd, Switzerland

1:00pm – 2:00pm

Lunch - *BioIndustry Exhibition Hall*

2:00pm – 3:30pm

Concurrent Sessions:
*Melbourne Exhibition Centre***5.
MEDTECH
Meeting Room 1, Level 2****New Technologies for Point of Care**

Recent advances in key enabling technologies such as nanotechnology, biotechnology and information technology promises tremendous opportunity and potential cost reductions for diagnostic applications in a range of different market sectors, including food, agricultural, environmental, pharmaceutical and medical.

**6.
HUMAN HEALTH
Meeting Room 3, Level 2****Maximising Australia's Investment in Medical Research – new approaches to discovery and commercialisation**

Australia through its strengths in the areas of medical research and innovation has demonstrated an ability to create local solutions that meet global challenges be it in the area of immunisation, oncology through to anti-virals.

**7.
GENERAL
Meeting Room 2, Level 2****Solutions that protect and improve performance**

Outsourcing and in-licensing is becoming the norm rather than the exception in drug discovery. This session will discuss the use of Contract Research Organisations (CROs) to reduce risk,

**8.
INVESTMENT / BUSINESS
Suite 1, Level 5****Venture Capital and Life Sciences in Australia Today. How does this compare with the Global Situation?**

This session will discuss the situation in Australia in regard to Venture Capital and Biotech. The panel will comprise the representatives of the main Venture Capital firms in Australia.

	<p>Medical diagnostics is of particular importance where the demand for low cost, highly accurate and widely available diagnostic tests is ever increasing, especially for the realisation of systems for Point of Care applications.</p> <p>The development of new Point of Care diagnostic products based on these new enabling technologies is very often a complex and demanding task. Solutions rely on a combination of factors: development of enabling technologies for the modular components; integration of key components into systems using novel, low cost manufacturing techniques; interfacing of systems to the external environment and most importantly, understanding the requirements of the user community and target markets. To achieve this successfully (both technically and commercially) is a significant challenge and requires the combination of multi skills and disciplines, often residing in multiple partners and companies.</p> <p>Chair: Dr David Lester, Director, Health Strategy and Coordination Group, CSIRO</p> <p>Speakers: Andrew Lysikatos, Chief Executive Officer, Axxin</p> <p>Dr Andrew Campitelli, Diagnostics Manager, MiniFAB (Aust) Pty Ltd</p> <p>Tom Stamp, Director, Blue Curve Pty Ltd <i>"What's in the mix? Combining novel IVD technologies, manufacturing methods and partnership arrangements for success"</i></p>	<p>Continuing to be a global player will require new ways of co-operating plus continuing support for the biotechnology sector from the Government. Research Australia, as the representative body for the Health research sector will outline its proposed new policy framework for encouraging greater co-operation within the research sector and by the research sector with industry.</p> <p>The subject will be discussed and debated by a panel of leading research participants from industry, government, academia and the research community. Research Australia will also discuss its recent polling on what the Australian population thinks of medical research, and how public support for research can be harnessed to contribute to industry growth</p> <p>Chair: Alex Gosman, Principal, Alex Gosman Consulting</p> <p>Speakers: Rebecca James, Chief Executive, Research Australia <i>"The state of the medical research industry in Australia and policy prescriptions for the future health"</i></p> <p>Dr Nicholas Gruen, Chief Executive Officer, Lateral Economics <i>"A new approach to collaboration in Health medical research"</i></p> <p>Peter Roberts, Senior Writer, The Australian Financial Review</p> <p>Dr Ashley Bates, Head of R&D Alliances Australia & New Zealand, GlaxoSmithKline <i>"A multinational perspective on investing and collaborating on Medical research in Australia"</i></p>	<p>overcome capacity constraints, and cost effectively access expertise or IP to meet project requirements. Recent changes in the outsourcing model both from the client and CRO perspective will be considered as will the likely direction it will take in the short and medium term. Some of the challenges involved in selecting the right CRO for your particular project, or stage of project, will be discussed, along with some of the consequences of getting it wrong and the benefits of getting it right.</p> <p>Chair: Dr Wayne Best, Managing Director, Epicchem Pty Ltd</p> <p>Speakers: Karen King, President, DSM Biologics, United States <i>"Biopharmaceutical Manufacturing Outsourcing Strategies and Trends"</i></p> <p>Dr Christopher Stewart, Director of Business Affairs, MPI Research, United States <i>"The Case-By-Case Regulatory Factor: What Does It Mean For Small Molecule Development?"</i></p> <p>Craig Rogers, Chief Commercial Officer, Nucleus Network</p>	<p>Chair and speaker: Dr Michael Hirshorn, Director, Four Hats Capital</p> <p>Speakers: Dr Andrew Baker, Partner, GBS Venture Partners</p> <p>Dr David Fisher, Managing Director, Brandon Capital Partners</p> <p>Dr Carrie Hillyard, Partner, CM Capital</p> <p>Fiona Pak Poy, General Partner, Innovation Capital</p> <p>Karl Handelsman, Managing Director, CMEA Capital, San Francisco, United States</p>
--	---	--	---	---

3:30pm – 4:00pm Afternoon Tea - BioIndustry Exhibition Hall

<p>4:00pm – 5:30pm</p> <p>Concurrent Sessions: <i>Melbourne Exhibition Centre</i></p>	<p>9A. GENERAL Meeting Room 1, Level 2</p> <p>4:00pm – 5:00pm</p> <p>Busting the myths about gene patenting</p> <p>Chair: Geraldine Farrell, Special Counsel, Griffith Hack Lawyers</p>	<p>10. HUMAN HEALTH Meeting Room 3, Level 2</p> <p>Translating Hope into Help</p> <p>Translating Cancer Research into practical applications for patients</p> <p>Chair: Ian Thompson, General Manager, Amgen Australia Pty Ltd</p>	<p>11. AG / INDUSTRIAL / FOOD Meeting Room 2, Level 2</p> <p>Future-proofing Australia: Products for a sustainable bioeconomy</p> <p>This session will explore the opportunity and hurdles of building a biobased economy based on Australian technologies and resources. Speakers will address the</p>	<p>12. INVESTMENT / BUSINESS Suite 1, Level 5</p> <p>Innovative Business Development Models</p> <p>It can be tough out there in the world of early-stage business development – shrinking pools of venture capital, shrinking time-horizons in which to</p>
---	---	---	--	--

	<p>Speakers: Dr Tania Obranovich, Partner, Davies Collison Cave <i>"Gene Patenting: Fact vs Fiction"</i></p> <p>Dr Julian Clark, Head of Business Development, Walter and Eliza Hall Institute <i>"Do patents hinder research? A practical perspective."</i></p> <hr/> <p style="text-align: center;">9B. GENERAL Meeting Room 1, Level 2</p> <p style="text-align: center;">5:00pm – 5:30pm</p> <p style="text-align: center;">Takeover Strategies Workshop</p> <p>This session will be facilitated by Peter Howard and Andrew Gaffney, both partners of Middletons who have had lead roles in a number of recent schemes and takeovers in the biotechnology industry. The session will include: a comparison of takeovers verses scheme structures and other exits; advantages and disadvantages of takeovers and schemes of arrangements; other relevant considerations; and strategic initiatives such as driving value. Informative but with a light humorous touch.</p> <p>Narrator: Dr Stewart Washer, Investment Manager, IB Managers</p> <p>Facilitators: Peter Howard, Partner Middletons</p> <p>Andrew Gaffney, Partner, Middletons</p>	<p>Professor Sean Grimmond, Director, Queensland Centre for Medical Genomics, Institute for Molecular Bioscience, The University of Queensland <i>"The Potential of Personal Cancer Genomics"</i></p> <p>Associate Professor David Thomas, Medical Oncologist / Head, Sarcoma, Peter MacCallum Cancer Centre <i>"Genomics and cancer medicine: paradigm shifts in evolution"</i></p> <p>Dr Pamela Pollock, Vice Chancellor Senior Research Fellow, Cancer Program, Institute of Health and Biomedical Innovation, Queensland University of Technology <i>"FGFR2 mutations in endometrial cancer: prognostic and therapeutic implications for the patient"</i></p>	<p>production of chemicals, for the pharmaceutical and industrial chemicals sectors. The production of industrial polymers from renewable feedstocks will be examined. Lastly, the role of specialised biofuels, in this case, aviation jet fuels will be considered.</p> <p>Chair: Dr Dianne Glenn, Principal, Corelli Consulting</p> <p>Speakers: Dr Ann Roberts, Project Manager, Plantic Technologies Ltd</p> <p>Dr Jens Kroemer, Australian Institute for Bioengineering & Nanotechnology (AIBN) The University of Queensland</p> <p>Dr William Lyons, Vice President and General Manager, Boeing Research & Technology Australia</p>	<p>demonstrate return on investment, and a shrinking range of support from Government agencies. But researchers around the world are continuing to expand the boundaries of existing knowledge, and the relentless drive for growth in the business community needs constant stoking with new ideas. How are our leading practitioners bridging the divide between producers and consumers of early-stage technology, and adapting to the ever-changing landscape?</p> <p>In this session, we will hear from three speakers who are at the coal-face of early-stage business development. We will explore the strategies they are using to keep up the flow of business development activity, and discuss fresh approaches to some long-standing challenges. Using case studies which draw on first-hand experiences, we will challenge attendees to think about how these approaches could be applied in their own settings.</p> <p>Chair and speaker: Dr Charlie Day, Chief Executive Officer, Melbourne Ventures</p> <p>Speakers: Dr James Dromey, Business Development Manager, Walter and Eliza Hall Institute</p> <p>Dr Dean Moss, General Manager Life Sciences, UniQuest</p> <p>Josh Hexter, Executive Director In-Licensing, BioLineRx Ltd, Israel</p>
5:30pm – 7:00pm	<p>INTERNATIONAL RECEPTION <i>BioIndustry Exhibition Hall</i></p>			
7:00pm – 8:00pm	<p>AUSBIOTECH 2010 EVENT PARTNERS VIP RECEPTION Clarendon Room, Level 5, Melbourne Exhibition Centre <i>Strictly by invitation only</i></p>			

THURSDAY 21 OCTOBER

7:30am – 9:00am	SATELLITE EVENT PricewaterhouseCoopers Breakfast Meeting Room 212, Melbourne Convention Centre <i>Strictly by invitation only</i>			
8:00am – 9:00am	SATELLITE EVENT Copenhagen Capacity – “Coffee-and-Danish” With a presentation on Medicon Valley Suite 2, Level 5, Melbourne Exhibition Centre <i>All delegates welcome to attend</i>			
9:00am – 10:00am <i>Auditorium, Level 2, Melbourne Exhibition Centre</i>	PLENARY 3 - Millis Oration – Sponsored by CSL Limited Introduction: Dr Deborah Rathjen, Chair, AusBiotech Ltd Introduction of Millis Orator: Dr Andrew Cuthbertson, Chief Scientific Officer, CSL Limited Speaker: Professor Nadia Rosenthal, Director, Australian Regenerative Medicine Institute, Monash University <i>“Recent progress in regenerative medicine”</i>			
10:00am – 10:30am	Morning Tea - BioIndustry Exhibition Hall			
10:30am – 12:00pm <i>Concurrent Sessions: Melbourne Exhibition Centre</i>	<p style="text-align: center;">13. MEDTECH Suite 1, Level 5</p> <p style="text-align: center;">Strategies for successful biomarker and companion diagnostics development</p> <p>The speakers will provide new information on three main aspects of biomarker development: Regulatory considerations for biomarker development. To be useful in clinical or other settings a biomarker must be accepted by the regulatory agencies. Biomarker regulatory strategies would be discussed including the possibility of incorporating formal validation by the regulatory agencies Biostatistics for biomarkers Appropriate statistical approaches for biomarker development would be provided. Development of companion diagnostics (Theranostics) Information on the regulatory and clinical challenges facing the development of companion diagnostics.</p> <p>Chair: Dr Matthias Schuster, Scientific Director Dx Assays, Singapore</p> <p>Speakers: Dr Hiram Chipperfield, Consultant, ERA</p>	<p style="text-align: center;">14. HUMAN HEALTH Meeting Room 2, Level 2</p> <p style="text-align: center;">Big Pharma Scouts – what they want and what you get</p> <p>This session will outline what big pharma are looking for and how to interface with their local scouts.</p> <p>Chair: Glenn Cross, Chief Operating Officer, AusBiotech Ltd</p> <p>Speakers: Dr Phil Kearney, Director, Licensing & External Research, Merck & Co., Inc.</p> <p>Dr Ashley Bates, Head of R&D Alliances Australia & New Zealand, GlaxoSmithKline</p> <p>Dr Daniel Grant, Director, Asia R&D Business Development, Pfizer Australia</p> <p>Dr Stella Xu, Executive Director, Roche Partnering Asia, Shanghai, China</p>	<p style="text-align: center;">15. GENERAL Meeting Room 1, Level 2</p> <p style="text-align: center;">Investors Unplugged: Everything you’ve wanted to ask a fund manager, but were afraid to ask</p> <p>An interactive forum designed to enable management teams to query venture and public investors from Australia, Europe and the U.S. The goal of this session is to encourage dialogue and promote candid, informal conversation between management teams and portfolio managers.</p> <p>Chair: Hershel Berry, Managing Partner, Blueprint Life Sciences, United States</p> <p>Panellists: Karl Handelsman, Managing Director, CMEA Capital, United States</p> <p>Oleg Nodelman, Portfolio Manager/Partner, Biotechnology Value Fund, United States</p> <p>Dr Axel Polack, General Partner, TVM Capital GmbH, Germany</p>	<p style="text-align: center;">16. INVESTMENT / BUSINESS Meeting Room 3, Level 2</p> <p style="text-align: center;">Future global trends in the life sciences industry – industry & legal trends</p> <p>The aim of the session is to assist the biotech industry to gain insights into global trends in this area and provide them with the depth of our knowledge in Australia and the United States. The audience will receive a snapshot of the market trends across the life sciences sector in the United States as well as key legal implications to consider when operating in an Australian and global market.</p> <p>Chair: Tony Conaghan, Lead Partner, Intellectual Property & Technology Practice, DLA Phillips Fox – Australia</p> <p>Speakers: Dr Lisa Haile, Partner Life Sciences Practice, DLA Piper - United States Bruce Jenett, Partner Life Sciences</p>

	<p>Consulting <i>"Integrating biomarkers into drug development: the importance of a suitable regulatory strategy"</i></p> <p>Dr Mervyn Thomas, Director, Althomics Pty Ltd <i>"Key Processes for Biomarker Discovery and Validation"</i></p> <p>Nick Gatsios, Managing Director & Executive Director (Australia), HealthLinx <i>"The role of biomarkers and diagnostics in providing better health outcomes"</i></p>		<p>Rajeev Shah, Partner, RA Capital Management LLC, United States</p> <p>Dr Rudolf Gyax, Managing Partner, Nextech Venture Ltd, Switzerland</p> <p>Lawrence Gozlan, Chief Executive Officer, Scientia Capital, United States</p>	<p>Practice, DLA Piper - United States</p> <p>Alex Gosman, Principal, Alex Gosman Consulting</p> <p>Dr Gabby Fennessy, Manager, Policy and Strategy, Research Australia</p> <p><i>Sponsored by DLA Phillips Fox</i></p>
<p>12:00pm – 1:00pm</p> <p><i>Auditorium, Level 2, Melbourne Exhibition Centre</i></p>	<p>PLENARY 4 - Introduction: Dr Joshua Funder, Partner, GBS Venture Partners</p> <p>Speaker: Dr Rob Armstrong, Vice President, Global External Research and Development, Eli Lilly and Company, United States <i>"New Era of Innovation Partnerships"</i></p>			
<p>1:00pm – 2:00pm Lunch – BioIndustry Exhibition Hall</p>				
<p>2:00pm – 3:30pm</p> <p>Concurrent Sessions: <i>Melbourne Exhibition Centre</i></p>	<p>17. MEDTECH Meeting Room 1, Level 2</p> <p>Developing Award Winning Medical Devices</p> <p>Chair: Dr Greg Roger, Chief Executive Officer, Advanced Surgical Design & Manufacture</p> <p>Speakers: Anthony Honeyfield, Design Director, Design + Industry <i>"Design + Industry are the largest privately owned product design and engineering consultancy in Australia. Design + Industry have won more than 100 industry awards for their clients through their commitment to design and engineering excellence. Find out how D+I develops successful medical devices?"</i></p> <p>Adam Panarello, Engineering Projects Manager (Hardware), Telemedcare Pty Ltd</p> <p>Lusia Guthrie, Chief Executive Officer & Managing Director, LBT Innovations Ltd <i>"LBT Innovations has successfully brought its MicroStreak technology to market: can other companies learn from this? Is it a recipe for successful medical device commercialisation?"</i></p> <p>David Mulcahy, Vice President Product Development, ResMed Ltd</p>	<p>18. HUMAN HEALTH Meeting Room 2, Level 2</p> <p>Understanding the implications of the rapidly evolving US healthcare and regulatory environment</p> <p>The regulatory and commercialisation pathway for both biologics and small molecules is changing almost daily as the full implications of the 2,700 page healthcare reform package are unveiled and as the Obama administration introduces other initiatives designed to 'bend the cost curve'. It's now a brave new world in the US and Australian biotechs need to understand the new requirements, complications and hurdles imposed by the new regulatory environment in the world's most important pharma market.</p> <p>Chair: Peter Molloy, President, Aquarius Consulting, Nevada, United States <i>"The implication for biotech-pharma deal flow"</i></p> <p>Jayson Slotnik, Counsel, Foley Hoag LLP, Washington DC, United States <i>"Healthcare reform: what happened, what's still happening and where are we headed?"</i></p> <p>Hathaway Russell, Patent Attorney, Foley Hoag LLP, Boston, United States</p>	<p>19. AG / INDUSTRIAL / FOOD Meeting Room 3, Level 2</p> <p>Evidence based complementary medicines for human and animal use: International Trends and Opportunities in Integrative Health</p> <p>Consumers are demanding it, government policy and regulatory changes are afoot and the multinational pharmaceutical industry is investing heavily in integrative approaches to prevention and cure. Growing international demand for high quality complementary medicines, with a sound scientific base of evidence, is attracting considerable investment.</p> <p>This session will discuss international trends, the fast changing regulatory environment in Australia and Canada and models for strategic co-development partnerships required to build a successful global complementary medicines business. Acknowledging the growing importance of complementary medicines, how can the broader Life Sciences community contribute to its effective integration with traditional biotechnological and pharmaceutical approaches to health.</p> <p>Session speakers will include globally focussed Canadian companies investing</p>	<p>20. INVESTMENT / BUSINESS Suite 1, Level 5</p> <p>How does the Australian public market react to news?</p> <p>The Life-science Australian public market is both only small in scale and receives limited analyst and media coverage. Consequently announcements and news may be interpreted and communicated to the public via a small number of sources. This session explores the public's ability to analyse newsflow and the affect of analyst/media coverage. Format will include a case study from an ASX listed company, examining its shareprice movements vs. news flow.</p> <p>Chair: Ben Gust, Investment Manager, GBS Venture Partners</p> <p>Speakers: David Blake, BioShares Michael Lusic, Business Director, Wilson HTM Corporate Finance Dr Greg Collier, Chief Executive Officer and Managing Director, ChemGenex Pharmaceuticals</p>

		<p><i>"The changing landscape of US regulatory and patent law post healthcare reform"</i></p> <p>Dr Paul Ashton, President and CEO, pSivida Corp., United States <i>"The changing pharma-biotech dealmaking landscape in the US"</i></p>	<p>heavily in R&D and international collaborations.</p> <p>Chair: Lawrence Bremner, Managing Director, The Big Well</p> <p>Mr Graeme McRae, Chief Executive Officer, Bioniche Life Sciences, Canada <i>"The Regulatory Environment for Human and Animal Therapies and the Advantages of Complementary Medicine Alternatives"</i></p> <p>Megan Thomas, Jamieson Laboratories Limited, Ontario, Canada <i>"Opportunities in the Canadian Natural Health Product Marketplace"</i></p> <p>Dr Lee Ann Murphy, Executive Director, Manitoba Agri-Health Research Network (MAHRN), Manitoba, Canada <i>"The Canada Climate Advantaged Diet: a business case for an innovative approach to managing cardiovascular disease (CVD) and emerging chronic illnesses"</i></p> <p>Dr Chris Wahl, Director Business Development, Micropharma, Canada <i>"The road to the world's first and only clinically proven Heart Health Probiotic"</i></p>	
2:30pm – 5:30pm	<p>AUSBIOTECH 2010 TRADE AFTERNOON BioIndustry Exhibition Hall</p> <p>The AusBiotech BioIndustry Exhibition is the largest biotechnology exhibition assembled in Australia. The exhibition showcases the latest in business and product services, equipment, instrumentation, devices and state-of-the-art technology. The Trade Afternoon is offered in addition to general access of the BioIndustry Exhibition for exhibitors and delegates. This time has been allocated specifically for exhibitors to invite guests and for graduate and undergraduate students to attend and engage with industry.</p>			
3:30pm – 4:00pm	<p>Afternoon Tea - BioIndustry Exhibition Hall</p>			
4:00pm – 5:30pm	<p>21. GENERAL Meeting Room 3, Level 2</p> <p>Credible and incredible! How to communicate with investors, regulators and prescribers</p> <p>At this session, nationally and internationally recognised experts will identify what you should and shouldn't do when communicating with investors, regulators, and prescribers. Our experts will highlight specific communication tactics for each audience and what incredible means to each of them. They will also reinforce the strategic and commercial importance of</p>	<p>22. HUMAN HEALTH Meeting Room 2, Level 2</p> <p>Research Ethics & Governance – State initiatives for global trials</p> <p>Initiatives towards enabling timely commencement of clinical trials in Australia have been undertaken by state jurisdictions with the aim of harmonising processes for ethics and governance approvals, which contributes to making Australia a location of choice for trials.</p> <p>This session will include an overview from</p>	<p>23. AG / INDUSTRIAL / FOOD Meeting Room 1, Level 2</p> <p>Plant biotechnology in Support of the Millennium Development Goals</p> <p>Chair: Dr Murray McLaughlin, President & CEO, Sustainable Chemistry Alliance, Ontario, Canada</p> <p>Speakers: Professor German Spangenberg, Executive Director, Biosciences Research Division, Department of Primary Industries & Professor, Plant Genetics and Genomics</p>	<p>24. INVESTMENT / BUSINESS Suite 1, Level 5</p> <p>Deal or No Deal?: Option Based Partnering Deals</p> <p>Biotech-Pharma partnering is recovering its high level of partnering activity post GFC. Big pharma continues to manage risk and opportunity with the externalisation of their R&D engines. Deal structures are increasingly risk modified, in licensees' and acquirers' favour. In particular, option based deal structure are becoming a norm, with the</p>

	<p>providing all audiences with credible material. Unethical communication practices from Australians have already been featured in the New York Times and Wall Street Journal – investors, regulators, and prescribers don't need to read about another “blunder from down under”! Attend this session to make sure you don't make the next one.</p> <p>Chair: Dr Christine Wichems, Medical Communications Manager, CSL Limited</p> <p>Speakers: Andy Jane, Partner, CM Capital</p> <p>Judy Develin, Coordinator, Market Authorisation Group, Therapeutic Goods Administration</p> <p>Associate Professor Karen Woolley, CEO, ProScribe Medical Communications</p>	<p>the Victorian Department of Health, NSW Health and Queensland Health on their state-based approaches to single ethical review. Joint initiatives across these three states will be described, including standard indemnity, trial agreements and guidance, use of the same IT platform and coordinated development of site authorisation processes.</p> <p>Chair: Bill Karanatsios, Client Relationship Manager, Public Healthcare and Medical Research, Victorian Managed Insurance Authority</p> <p>Speakers: Dr Suzanne Hasthorpe, Manager, Department of Health, Victoria</p> <p>Sue Jenkins-Marsh, Principal Project Officer, Queensland Health</p> <p>Dr Jo Mitchell, Associate Director Research, Ethics and Public Health Training, NSW Health</p> <p>Mitch Kirkman, Manager- Process, Training and Quality, Novartis Pharmaceuticals, Australia Pty Limited</p>	<p>La Trobe University <i>“Plant gene technology in a climate of change for food, feed and energy”</i></p> <p>Dr TJ Higgins, Honorary Fellow, CSIRO <i>“Protecting Food Legumes from Insect Damage”</i></p> <p>Professor Emeritus Ingo Potrykus, Chairman Humanitarian Golden Rice Board & Network, Switzerland <i>“GMO's will support the Millennium Goals only if 'extreme precautionary regulation' is abandoned”</i></p>	<p>full engagement of the partner dependent on a significant, short-term milestone. This session examines recent deals following this trend and discusses views from a range of stakeholders on both sides of these deals – investors, big pharma & biotech deal makers, analysts.</p> <p>Chair: Robin Coleman, Principal, PharmBio Deals</p> <p>Speakers: Dr Leigh Farrell, VP Business Development, Biota Holdings Ltd</p> <p>Dr Richard Treagus, Chief Executive Officer, AcruX Ltd</p> <p>Dr Joshua Funder, Partner, GBS Venture Partners</p> <p>Dr Shane Storey, Analyst – Healthcare and Biotechnology, Wilson HTM Investment Group</p> <p>Dr Fintan Walton, Founder and Chief Executive Officer, PharmaVentures, United Kingdom</p>
7:00pm – 11:30pm	<p>AUSBIOTECH 2010 CONFERENCE DINNER <i>Melbourne Convention Centre – Level 2, Rooms 201 & 202</i> <i>Pre-dinner drinks in Foyer from 7.00pm</i></p> <p><i>Sponsored by Pfizer</i></p>			

FRIDAY 22 OCTOBER

<p>9:00am – 9:30am</p> <p><i>Suite 1, Level 5, Melbourne Exhibition Centre</i></p>	<p>PLENARY 5 – Introduction: Michael Quinn, Managing Partner, Innovation Capital</p> <p>Speaker: Dr John W. Holaday, Managing Director and CEO, QRxPharma Limited <i>“Making a business out of science...lessons learned”</i></p>		
<p>9:30am – 11:00am</p> <p>Concurrent Sessions: <i>Level 5, Melbourne Exhibition Centre</i></p>	<p>25. GENERAL Suite 2, Level 5</p> <p>Building reputation to drive corporate strategy: A masterclass in biotech communications</p> <p>This interactive masterclass in biotechnology communications will bust the myth that scientists, businesses and investors make decisions based solely on data. Veteran communicators from pharma and biotech will provide examples and demonstrate how perceptions create reputations and brands. They will explore ways that</p>	<p>26. AG / INDUSTRIAL / FOOD Clarendon Room, Level 5</p> <p>Functional Foods</p> <p>Chair: Peter Hobman, General Manager, MG Nutritionals Ltd</p> <p>Speakers: Joe Lederman, Managing Principal, FoodLegal <i>“Health and Nutritional Claims for Food: A review of current impediments”</i></p>	<p>27. INVESTMENT / BUSINESS Suite 1, Level 5</p> <p>Think Locally, Act Globally: Successfully taking Australian intellectual capital to the world stage</p> <p>This session will provide three speakers and a moderated panel discussion of the strategies, both theoretical and practical, for commercialising the inventions of Australian companies successfully on to the world stage.</p> <p>It will provide the perspective of at least two successful</p>

	<p>companies, large and small, have successfully built and managed their reputation and in some cases used it to support and drive their strategy. Best and worst practise will be shown, providing valuable tips on how best to build trust and confidence, as well as using emotion to engage and persuade stakeholders.</p> <p>Chair and speaker: Sue Charles, Managing Partner, College Hill Life Sciences, London, United Kingdom</p> <p>Speakers: Margaret Stuart, Director, Margaret Stuart and Associates</p> <p>Peter Sandbach, Head of Communications, Roche Partnering, F. Hoffmann-La Roche AG, Switzerland</p> <p>Nick Woolf, Non Executive Director, Phylogica Limited</p>	<p>Amanda Jones, Principal, Watermark Patent & Trademark Attorneys <i>"Food for thought - the management of functional foods as intellectual assets"</i></p> <p>Dr Andrew Kelly, Executive Director, BioPacificVentures, New Zealand <i>"How to attract investment (and why it's so damn difficult!)"</i></p>	<p>Australian companies, at least one which has "gone it alone" in taking their technology to the world, and the other of which has, alternately, commercialised their technology through partners. The session will not assume that patent protection is necessary and will provide a roadmap for successful commercialisation from a company that has not relied on patent protection for its products. The speakers will address:</p> <ul style="list-style-type: none"> • finding the right business model for technology exploitation, • how to find the right partner, • what to do when partnerships don't go as planned, • getting through the funding drought in early stage technology development <p>Chair: Karen Sinclair, Principal, Watermark Patent & Trade Marks Attorneys, and President, Licensing Executives Society of Australia and New Zealand, Inc.</p> <p>Speakers: Dr Simon Tucker, Vice President Research, Biota Holdings Limited <i>"IP Management and commercialisation – knowing your customer"</i></p> <p>Brad O'Connor, Chief Executive Officer, CogState Limited</p> <p>Mel Bridges, Chairman and Company Director <i>"Management of tacit knowledge – a global perspective"</i></p>
--	--	---	---

11:00am – 11:30am Morning Tea - BioIndustry Exhibition Hall

<p>11:30am – 1:00pm</p> <p>Concurrent Sessions: <i>Level 5, Melbourne Exhibition Centre</i></p>	<p>28. MEDTECH Suite 2, Level 5</p> <p>Integration of Wireless Medical Devices</p> <p>Chair: Dr Scott Martin, Leader, Biomedical Manufacturing Research Theme, CSIRO</p> <p>Speakers: Warren Bingham, President – Australia / New Zealand, Given Imaging Pty Ltd <i>"Smile – you've just swallowed a camera"</i></p> <p>Peter Lewis, General Manager Business Development, Hydrix <i>"Wireless Health – Trends, Technology & Take Up"</i></p> <p>Dr Jason Chaffey, Chief Technology Officer, bluechiip Pty Ltd <i>"Tracking technologies for biobanks - more than inventory control"</i></p>	<p>29. HUMAN HEALTH Clarendon Room, Level 5</p> <p>India – beyond contract manufacturing</p> <p>With rising costs and low productivity in successful new drug launches globally, Asian CROs (in particular Indian and Chinese) are already playing a significant role in driving innovation. While India has emerged as a major global player (second only to the US) in the FDA approved contract manufacturing base since the 80s and 90s, it is quickly emerging as a mature destination to outsource for high quality, low cost early stage R&D and preclinical work. In addition, access to modern, high quality hospital infrastructure operated by well-trained clinicians as well as availability of a large population of drug-naive patients in all major disease areas, has enabled India to carve a growing share of global multi-centric clinical trials market. This session gives an overview of what the Indian CRAMs industry has looked like in the past, its development today and it's vision for the future as well as opportunities for funding.</p> <p>Chair and speaker: Mr Swapan Bhattacharya, Managing</p>	<p>30. INVESTMENT / BUSINESS Suite 1, Level 5</p> <p>Creating Global Value in Product Development: from Proof of Principle to Regulatory Strategy</p> <p>This session is designed to enlighten attendees on ways in which product development can be streamlined to enable global acceptability of data and thus accelerate product development. From discussions of the early preclinical phase of the product life cycle, to formal nonclinical and clinical development and then to regulatory filings, this session will provide tips on ways to maximize product development results, with the added benefit of controlling costs for the overall program. Within the individual topics, advice on best practices and approaches will be provided, along with points for consideration as products move from research and development through to clinical phases. The Speakers hope to generate good discussion during a Question and Answer period at the end of the session.</p> <p>Chair: Dr Gabriel Kremmidiotis, Vice President Discovery</p>
---	--	---	---

		<p>Director, TCG Lifesciences, West Bengal, India <i>'India as a Global Innovation Hub for the Pharmaceutical Industry'</i></p> <p>Speakers: Dr Julia Hill, Director, Mantrax Ventures <i>'Working with India – myths, reality and the changing landscape'</i></p> <p>Dr Alistair Draffan, Director Drug Discovery, Biota Holdings Ltd <i>'Building strong research collaborations with India: how to hit a 6'</i></p> <p>Dr Arun Bhatt, President, Clininvent Pvt Ltd, India <i>'India – a Strategic Imperative for Clinical Trials'</i></p> <p>Dr Lewis Schulz, Chief Operating Officer, Hatchtech Pty Ltd <i>'India – a Strategic Imperative for Clinical Trials'</i></p>	<p>Research, Bionomics Limited</p> <p>Speakers: Dr Valentia Lee-Brotherton, Director, Toxicology, Ashuren Health Sciences, Canada <i>'Benchtop to Market: Introduction to Global Planning in Product Development'</i></p> <p>Dr Ken Draper, Senior Director, Scientific Operations, LAB Research Inc., Canada <i>'Toxicology Considerations for Effective Nonclinical Product Development'</i></p> <p>Nicholas Peace, Investment Director, Starfish Ventures Pty Ltd</p> <p>Dr Pete Smith, Chief Executive Officer, Alchemia Limited</p> <p>Dr Michael Thurn, Chief Executive Officer, Mimetica Pty Ltd</p>
<p>1:00pm – 2:30pm AUSBIOTECH 2010 CLOSING RECEPTION and WELCOME TO AUSBIOTECH 2011 <i>BioIndustry Exhibition Hall</i></p>			
<p>2:00pm – 3:00pm</p>	<p>AUSBIOTECH LTD ANNUAL GENERAL MEETING <i>Suite 1, Level 5</i> <i>Melbourne Exhibition Centre</i></p> <p>All AusBiotech members are encouraged to attend and participate at the Annual General Meeting.</p>		